The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IASLC TTLC 2022 | Radiotherapy highlights at TTLC 2022
Charles Simone, MD, FACRO, New York Proton Center & Memorial Sloan Kettering Cancer Center, New York, NY, provides some of his highlights presented at the 2022 Targeted Therapies of Lung Cancer Meeting (TTLC 2022), including advances in combining radiotherapy and immunotherapy for thoracic and lung cancer. Ongoing trials investigating pembrolizumab and radiotherapy will determine whether radiotherapy will make cold tumors more susceptible to anti-PD-L1 therapies. This interview took place at TTLC 2022.
